BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?

Boston Scientific (BSX) is exhibiting stronger operational momentum and analyst confidence within the expanding MedSurg sector, with shares up 35.2% over the past year and a raised 2025 sales growth outlook of 15-17% driven by gains in Endoscopy, Urology, Neuromodulation, and structural heart. Conversely, Medtronic (MDT), despite expanding its Hugo RAS system and showing strong operational performance, has seen shares rise only 7.4% with declining EPS estimates, though its 3.1X forward P/S offers a more attractive valuation compared to BSX's 7.5X. This positions BSX as a growth-oriented investment and MDT as a potential value opportunity.

Analysis

The analysis presents a clear dichotomy in the MedSurg sector between Boston Scientific (BSX) and Medtronic (MDT), framed against a market backdrop of a projected 9.54% CAGR from 2025 to 2030. Boston Scientific is demonstrating significant operational momentum and investor confidence, underscored by a 35.2% share price increase over the past year. This is fueled by market share gains across its Endoscopy, Urology, and Neuromodulation segments, plus 24% growth in its WATCHMAN device sales. The company's strength is further supported by a raised full-year 2025 guidance, projecting 15-17% net sales growth and an implied 15.9% EPS improvement, despite a potential $200 million tariff impact. In contrast, Medtronic exhibits solid operational performance, including a 210 bps operating margin improvement and expansion of its Hugo robotic surgery system into 30 countries, but this has not translated into strong market performance, with its stock up only 7.4%. Analyst sentiment for MDT is deteriorating, evidenced by downward EPS estimate revisions and a projected organic revenue growth of just 5% for fiscal 2026. This performance gap creates a valuation disparity: BSX trades at a premium 7.5X forward P/S, while MDT appears undervalued at 3.1X, below the sector average of 5.4X.

Key Decisions for Investors

• Investors with a growth-focused strategy should consider Boston Scientific, given its superior operational momentum, strong forward guidance, and positive analyst estimate revisions, while remaining aware of its premium valuation.
• Value-oriented investors may find Medtronic appealing due to its discounted price-to-sales multiple compared to the sector, but should proceed with caution given the stock's significant underperformance, downward estimate revisions, and a weaker growth outlook.
• Key catalysts to monitor include the impact of the $200 million tariff on BSX's profitability and the progress of MDT's Hugo robotic system's FDA approval, which could be a significant event to shift its market sentiment.